Study S001821

Optimization of Albuminuria Lowering Therapies to Individual Patients With CKD Using FINErenone and SEmaglutide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07819227
Acronym: FINESSE-CKD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 41
Start: 2025-02-11
Primary completion: 2026-08-31
Lead sponsor: University Medical Center Groningen
Conditions: Chronic Kidney Disease
Interventions: DRUG:Finerenone (BAY 94-8862); DRUG:Semaglutide 14 MG [Rybelsus]; DRUG:Finerenone and Semaglutide
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2023-506434-69-00; NIH:2023

Registered primary outcomes

Proportion of patients with ≥30% reduction in urinary albumin:creatinine ratio (UACR) from baseline during monotherapy with finerenone or semaglutide or combined treatment with finerenone-semaglutide. [From baseline to the end of study (Week 37)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.